Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients ...Middle East

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi...

Hence then, the article about sirnaomics announces completion of stp707 phase i clinical study with strong safety profile and disease activity for the treatment of pancreatic cancer patients was published today ( Friday 28/06/2024 - 08:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients )

Also on site :

• UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
• AI boom fuels fears of an industry bubble (VIDEO)
• Scott Ritter say he was ‘de-banked’